沙利度胺联合地塞米松治疗老年多发性骨髓瘤的疗效分析及不良反应

吴宁宁

doi:10.3969/j.issn.1006-0111.2012.06.014

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

沙利度胺联合地塞米松治疗老年多发性骨髓瘤的疗效分析及不良反应

吴宁宁

文章导航 > 药学实践与服务 > 2012 > 30(6): 447-448

吴宁宁. 沙利度胺联合地塞米松治疗老年多发性骨髓瘤的疗效分析及不良反应[J]. 药学实践与服务, 2012, 30(6): 447-448. doi: 10.3969/j.issn.1006-0111.2012.06.014

引用本文:

吴宁宁. 沙利度胺联合地塞米松治疗老年多发性骨髓瘤的疗效分析及不良反应[J]. 药学实践与服务, 2012, 30(6): 447-448. doi: 10.3969/j.issn.1006-0111.2012.06.014

WU Ning-ning. Therapeutic effect and adverse reaction of Thalidomide combined with dexamethasone in elderly patients with multiple myeloma[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 447-448. doi: 10.3969/j.issn.1006-0111.2012.06.014

Citation:

WU Ning-ning. Therapeutic effect and adverse reaction of Thalidomide combined with dexamethasone in elderly patients with multiple myeloma[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 447-448. doi: 10.3969/j.issn.1006-0111.2012.06.014

沙利度胺联合地塞米松治疗老年多发性骨髓瘤的疗效分析及不良反应

doi: 10.3969/j.issn.1006-0111.2012.06.014

吴宁宁

宁波市第二医院血液科, 浙江宁波 315000

Therapeutic effect and adverse reaction of Thalidomide combined with dexamethasone in elderly patients with multiple myeloma

WU Ning-ning

Department of Hematology, Second Hospital of Ningbo, Ningbo 315000, China

摘要: 目的观察沙利度胺联合地塞米松治疗老年多发性骨髓瘤的疗效和安全性。方法初治老年多发性骨髓瘤患者50例,均给予沙利度胺联合地塞米松治疗,沙利度胺起始剂量50 mg/次,1次/d,口服,根据患者耐受情况逐步增加剂量50 mg,至最大量200 mg/次,1次/日,口服;地塞米松20 mg/次,1次/日,第1~4天,第9~12天,第17~20天,静脉滴注,每28 d为1个疗程。治疗4个疗程后评定疗效。结果完全缓解15例,非常好的部分缓解12例,部分缓解13例,病情无变化5例,疾病进展5例,总有效率为80%。治疗过程中出现嗜睡l7例,便秘16例,疲乏16例,血糖升高10例,外周神经炎8例,皮疹3例,对症处理后均可耐受。结论沙利度胺联合地塞米松是治疗老年多发性骨髓瘤的有效方法。
- 沙利度胺 /
- 地塞米松 /
- 多发性骨髓瘤
Abstract: Objective To observe the efficiency and safety of thalidomide combined with dexamethasone in elderly patients with multiple myeloma. Methods A total of 50 elderly patients with multiple myeloma in initial treatment were administered thalidomide combined with dexamethasone. Thalidomide was administered at an initial dose of 50 mg once-daily orally followed by gradually increased in 50 mg according to patients' tolerance to a maximum of 200 mg once-daily orally, dexamethasone was administered at 20 mg once-daily IV in 1~4 d, 9~12 d and 17~20 d with 28 d as a course of treatment. The efficiency after 4 courses of treatment eva-luate was evauated. Results Complete remission were in 15 cases, immense partial remission in 12 cases, partial remission in 13 cases, no change in 5 cases and progression of disease in 5 cases. The total effective rate was 80%. During treatment, there were 17 patients suffering from hypersomnia, 16 onstipation, 16 lassitude, 10 increased blood sugar, 8 peripheral neuropathy and 3 rashes. All the patients could tolerant after expectant treatment. Conclusion It could be an effective method of thalidomide combined with dexamethasone in elderly patients with multiple myeloma.
- thalidomide /
- dexamethasone /
- multiple

[1]	沙信山,李永辉,张桂芳,等.小剂量沙利度胺联合长春地辛、吡喃阿霉素和地塞米松方案治疗老年多发性骨髓瘤[J].中华实用诊断与治疗杂志,2009,23(3):303.
[2]	中国多发性骨髓瘤工作组.中国多发性骨髓瘤诊治指南[J].中华内科杂志,2008,47(10):869.
[3]	Facon T, Mary JY, Pegourie B, et al. Dexamethasone-based regi-mens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy[J]. Blood,2006,107(4):1292.
[4]	Fujita J,Mestre JR,Zeldis JB,et al.Thalidomide and its analogues inhibit lipop1ysaccharide mediated linduction of cyclooxygenase 2[J].Clin Cancer Res,2001,7(11):3349.
[5]	顾惠慈.三氧化二砷联合化疗治疗难治复发多发骨髓瘤的临床疗效分析[J].实用诊断与治疗杂志,2006,20(12):918.
[6]	张之南.血液病诊断及疗效标准[M].第2版,北京:科学出版社,1998:73.

[1]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
[2]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[3]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[4]	毛智毅, 王筱燕, 陈晓颖, 汤逸斐. 度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
[5]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[6]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050

点击查看大图

计量

文章访问数: 7206
HTML全文浏览量: 261
PDF下载量: 2485
被引次数: 0

沙利度胺联合地塞米松治疗老年多发性骨髓瘤的疗效分析及不良反应

doi: 10.3969/j.issn.1006-0111.2012.06.014

吴宁宁

宁波市第二医院血液科, 浙江宁波 315000

收稿日期: 2012-02-21
修回日期: 2012-05-28

关键词:

沙利度胺 /

地塞米松 /

多发性骨髓瘤

摘要: 目的观察沙利度胺联合地塞米松治疗老年多发性骨髓瘤的疗效和安全性。方法初治老年多发性骨髓瘤患者50例,均给予沙利度胺联合地塞米松治疗,沙利度胺起始剂量50 mg/次,1次/d,口服,根据患者耐受情况逐步增加剂量50 mg,至最大量200 mg/次,1次/日,口服;地塞米松20 mg/次,1次/日,第1~4天,第9~12天,第17~20天,静脉滴注,每28 d为1个疗程。治疗4个疗程后评定疗效。结果完全缓解15例,非常好的部分缓解12例,部分缓解13例,病情无变化5例,疾病进展5例,总有效率为80%。治疗过程中出现嗜睡l7例,便秘16例,疲乏16例,血糖升高10例,外周神经炎8例,皮疹3例,对症处理后均可耐受。结论沙利度胺联合地塞米松是治疗老年多发性骨髓瘤的有效方法。